- Scientific misconduct revealed in high-dose
chemotherapy trials.
Last year Dr. Werner Bezwoda of the University of Witwatersrand in Johannesburg admitted that he falsified data in a study that showed bone-marrow transplantation and high-dose chemotherapy could prolong the lives of some women with breast cancer that spread to their lymph nodes. His admission and retraction of results came ......
- Missile radar targets breast cancer
Radar technology developed for the Strategic Defense Initiative to detect satellite-launched missiles also destroys breast cancer cells. Focused microwave thermotherapy kills cancer cells by heating them to about 115'F yet doesn't burn the skin, says Dr. Alan Fenn of M.LT.'s Lincoln Laboratory, inventor of the technology. The technique works because ......
- Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting.
NOV-002 Decreases Cisplatin-induced Nephrotoxicity, S-glutathionylates Serum Proteins in Mice, and Induces the Unfolded Protein Response Via Oxidative Signaling In Tumor Cells NEWTON, Mass. -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company, in collaboration ......
- Xanthus receives patent on lead anti-cancer compound
Xanafide amonafide.
Xanthus Life Sciences (Cambridge, MA) announced that it has received United States Patent 6,693,198, covering the company's lead cancer product, Xanafide amonafide (Xanafide), which is being developed in conjunction with Xanthus' metabolic predictors to enhance therapeutic outcome using individualized dosing regimens. "This new composition of matter patent gives Xanthus' protection ......
- Therion Biologics obtains rights to Biogen Idec
LFA-3.
Therion Biologics Corporation (Cambridge, MA) has licensed from Biogen Idec, Inc. (Cambridge, MA) patent rights relating to Lymphocyte Function Associated Antigen-3 (LFA-3). LFA-3 isa component of TRICOM, Therion's co-stimulatory system for optimizingimmune response against tumor cells. TRICOM is an integral component ofTherion's proprietary lead cancer vaccine candidates, PROSTVAC-VF and PANVAC-VF, ......
- Galenica acquisition finalized.
Australian Cancer Technology (Sydney, Australia) chairman Roger Aston and managing director Paul Hopper announced from New York that due diligence on the proposed US$5 million Galenica Pharmaceuticals (Birmingham, AL) acquisition was completed satisfactorily and final documentation signed today. The acquisition is now subject only to the approval of AustCancer shareholders ......
- Pharmaceutical companies focus on women
Before the year's end, Whitehouse Station-based Merck & Co. expects to submit a Biologics License Application with the FDA for a cervical cancer vaccine Gardasil. In a 12,000-patient Phase III trial, Gardasil - quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine - prevented 100 percent of high-grade cervical ......